Aurinia Pharmaceuticals AUPH Foreign Translation Gain (Loss) On Revaluation Of Finance Lease Liability
Foreign Translation Gain (Loss) On Revaluation Of Finance Lease Liability at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept auph:ForeignTranslationGainLossOnRevaluationOfFinanceLeaseLiability.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's foreign translation gain (loss) on revaluation of finance lease liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's foreign translation gain (loss) on revaluation of finance lease liability?
- Aurinia Pharmaceuticals (AUPH) reported foreign translation gain (loss) on revaluation of finance lease liability of $416K in Q1 2026.
- How has Aurinia Pharmaceuticals's foreign translation gain (loss) on revaluation of finance lease liability changed year-over-year?
- Aurinia Pharmaceuticals's foreign translation gain (loss) on revaluation of finance lease liability increased by 123.0% year-over-year, from -$1.81M to $416K.
- What does foreign translation gain (loss) on revaluation of finance lease liability mean?
- This represents the non-cash impact of currency exchange rate fluctuations on the valuation of finance lease liabilities denominated in foreign currencies. It highlights the sensitivity of the company's balance sheet to international market volatility. Investors monitor this to distinguish between operational performance and gains or losses driven purely by currency movements.